Why I Would Buy AstraZeneca plc And TT Electronics plc But Sell Lamprell Plc

Royston Wild explains why investors should — or should not — invest in AstraZeneca plc (LON: AZN), TT Electronics plc (LON: TTG) and Lamprell Plc (LON: LAM).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Today I am looking at the investment case for three London-listed movers.

AstraZeneca

Shares in AstraZeneca (LSE: AZN) (NYSE: AZN.US) have failed to recover from late April’s collapse, the medicines giant’s 2.8% slide today pushing it even further away from last month’s record peak of £48.63p per share. While ongoing worries over further revenues-crushing patent losses is quite rightly stoking investor nerves, I believe that for long-term investors AstraZeneca should prove a lucrative growth pick.

Indeed, AstraZeneca’s R&D operations keep on delivering — the firm expects to start Phase II testing on between 12 and 16 drugs this year, and to receive approval for up to 10 products. On top of this, I reckon that AstraZeneca’s transatlantic lab-building programme, scheduled for completion in 2018, should provide a significant boost to the company’s development profile.

So although AstraZeneca is anticipated to see earnings flatline in 2015, and slip 2% in the following year, I expect its rejuvenated lab operations to drive profits higher once again looking further ahead. And while the pharma play may not be the most jaw-dropping value pick in town — P/E multiples of 16.3 times and 16.5 times for this year and next are just above the benchmark of 15 times which represents decent bang for one’s buck — a prospective dividend of 290 US cents through to the close of 2016 produces a market-beating yield of 4.1%.

TT Electronics

Electronic components play TT Electronics (LSE: TTG) has cheered the market with a positive trading update today and was last dealing 7.3% higher. The Surrey firm advised that it has made “an encouraging start to the year despite the anticipated challenging market conditions,” with its order book remaining strong and overall trading matching expectations. As well, the business advised that its ‘Operational Improvement Plan’ was also on track, with restructuring expected to complete in the first half of 2017.

TT Electronics’ operational footprint covers a wide array of industries, including the aerospace, defence, transportation, industrial and medical sectors. And I believe this diversification should protect its long-term earnings prospects as global growth picks up. Indeed, the number crunchers expect TT Electronics to rebound from an estimated 31% earnings dip this year with a 14% advance in 2016. These figures leave TT Electronics trading on sunny P/E ratios of 14.8 times and 13.1 times for 2015 and 2016 correspondingly.

And the electronics boffins provide excellent value for dividend seekers, too. TT Electronics is expected to keep the dividend on hold around 5.5p per share this year, although a slight hike to 5.6p is chalked in for 2016. As a result the stock carries a mouth-watering 4.2% yield through to the close of next year.

Lamprell

Like TT Electronics, rig builder Lamprell (LSE: LAM) is also performing well in Tuesday business and was recently 2.6% higher. Although company veteran Peter Whitbread announced his departure from the board today, investor sentiment remains upbeat as Lamprell stacks up the contracts — indeed, Abu Dhabi’s National Drilling Company ordered a newbuild rig with the firm in late April.

Although the news has illustrated the benefits of Lamprell’s focus on the Middle East and North Africa, I believe that a backcloth of worsening supply/demand fundamentals in the oil market is likely to constrain spending by the industry’s key players still further in the coming years. This view is shared by the City, and Lamprell is consequently expected to punch a hefty 41% earnings slide in 2015. The bottom line is anticipated to stagnate in 2016.

These figures leave Lamprell changing hands on 12.8 times through to the close of next year, although I would consider a figure closer to the bargain benchmark of 10 times to be a fairer reflection of the risks facing the hardware builder.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young Caucasian woman with pink her studying from her laptop screen
Investing Articles

Here’s the dividend forecast for Lloyds shares

Dr James Fox walks through the dividend forecast for one of the most popular stocks on the FTSE 100. Despite…

Read more »

Young Black man sat in front of laptop while wearing headphones
Investing Articles

Hunting for passive income? Here’s a top FTSE 100 dividend growth share to consider!

Buying low-yielding shares like this FTSE dividend growth hero can be a great way to make a long-term passive income.

Read more »

Middle-aged white man pulling an aggrieved face while looking at a screen
Investing Articles

£10,000 invested in Tesla stock 2 weeks before the US election is now worth…

The US election represented a major turning point for Tesla stock, taking millions of shareholders on one hell of a…

Read more »

Middle-aged white man pulling an aggrieved face while looking at a screen
Investing Articles

This FTSE 250 trust is a high-risk, potentially-high-reward play

Typically, trusts offer a degree of stability due to their diversified nature. Dr James Fox explains why this FTSE 250…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

Up 47% from its 12-month low, is there any value left in Lloyds’ share price?

Lloyds’ share price has risen substantially over the past year, but it may still have significant value left in it.…

Read more »

Senior woman potting plant in garden at home
Investing Articles

£500 to invest a month? Here’s how a Stocks and Shares ISA could unlock a comfortable retirement

The tax benefits of the Stocks and Shares ISA can provide the foundations for significant long-term wealth creation. Here's how.

Read more »

Young female hand showing five fingers.
Investing Articles

5 reasons to consider buying this FTSE 100 stock like there’s no tomorrow

Ben McPoland highlights five reasons why he thinks this excellent FTSE 100 stock looks like a solid portfolio contender right…

Read more »

British flag, Big Ben, Houses of Parliament and British flag composition
Investing Articles

Down 83%! This FTSE 250 firm could now be a stock market takeover target

After a serious stock market slump, the boss of this FTSE 250 biotech company has reportedly highlighted its takeover exposure.

Read more »